Sign in

CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company

Taysha Gene Therapies, Inc.

Sign in to watch
Ticker
TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
843199512
Phone
(214) 612-0000
Business address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
  1. 4 Grant or award Director acquired 56,623 shares (grant or award)
  2. 4 Open-market buy 10% owner bought 750,000 shares at $2.75 ($2,062,500)
  3. 4/A Derivatives Options or other derivatives
  4. 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 29,843 shares (to pay taxes)
  5. 4 Grant or award Chief Executive Officer acquired 892,500 shares (grant or award)
  6. 4 Grant or award President and Head of R&D acquired 324,500 shares (grant or award)
  7. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 431,000 shares (grant or award)
  8. 4 Open-market buy 10% owner bought 1,333,333 shares at $2.25 ($2,999,999)
  9. 4 Grant or award Director acquired 49,220 shares (grant or award)
  10. 4 Grant or award Director acquired 49,220 shares (grant or award)
  11. 4 Grant or award Director acquired 49,220 shares (grant or award)
  12. 4 Grant or award Director acquired 49,220 shares (grant or award)
  13. 4 Shares withheld for taxes CHIEF FINANCIAL OFFICER gave up 1,288 shares (to pay taxes)
  14. 4 Grant or award Chief Financial Officer acquired 590,413 shares (grant or award)
  15. 4 Grant or award President and Head of R&D acquired 863,617 shares (grant or award)
  16. 4 Grant or award Chief Executive Officer acquired 1,184,688 shares (grant or award)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market buy 10% owner bought 100,000 shares at $1.63 ($163,000)

Page 2 of 6 · 120 filings